anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
With aging, skeletal muscle mass and performance decline leading to an increased risk of falls and physical disability. There is ongoing research on whether increasing dietary protein intake in older adults improves indices of muscle health and thus translates to a reduction in physical disability. A main concern is that high protein results in a large dietary acid load from the breakdown of protein to acidogenic byproducts, which could in turn promote muscle degradation particularly in older adults with age-related declines in renal excretion of acid. The scientific premise of this project is that the balance between the amount of protein in the diet (anabolic component) and the net acid load of the diet (catabolic component) in part determines whether the diet as a whole has a net anabolic or catabolic effect on muscle. Preliminary data have suggested that a daily alkaline salt supplement (potassium bicarbonate, KHCO3) lowered the dietary acid load and improved lower extremity muscle power in postmenopausal women. The investigator's central hypothesis is that higher protein intake plus a neutralizing alkaline salt will have additive effects on muscle performance and mass in older adults to either intervention alone. To test the hypothesis, the investigators will conduct a randomized, double-blind, placebo-controlled, 2x2 factorial study in which underactive men and women age 65 and older on baseline lower protein diets will be enrolled. Participants will assigned to one of four groups: either a whey protein supplement (to raise protein intake to 1.5 g/kg/d) with or without KHCO3 81 mmol/d or an isocaloric placebo supplement with or without KHCO3 81 mmol/d for 24 wks. The primary outcome is lower extremity muscle power at 24 weeks. Secondary outcomes are lower extremity muscle power at 12 weeks, muscle endurance at 12 and 24 weeks, physical performance at 24 weeks, lean mass at 24 weeks, and 24-hr urinary nitrogen excretion adjusted for nitrogen intake at 24 weeks. Exploratory outcomes will include a measure of muscle mass - D3-creatine dilution - and how it correlates with lean mass. Changes in these outcomes will be compared in the 4 groups. If successful, this research would represent a meaningful step in defining the circumstances under which protein has its greatest anabolic benefit.
The invention refers to genetic engineering and can be used in biotechnology, medicine, and agriculture for the manufacture of gene therapy products. Gene therapy DNA vector based on the gene therapy DNA vector VTvaflV carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB 3, and COL7A1 genes was constructed in order to increase the expression level of this therapeutic gene in humans and animals, while gene therapy DNA vector VTvafl7-KRT5, or VTvafl7-KRTl4, or VTvafl7-LAMB3, or VTvafl7-COL7Al has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, respectively. The gene therapy DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, which ensures its safe use for gene therapy in humans and animals. A method of obtaining the specified vector, the use of the vector, a strain of Escherichia coli carrying the specified vector, and a method of industrial production of the specified vector are also provided.
PCT No. PCT/US89/04247 Sec. 371 Date Jun. 7, 1991 Sec. 102(e) Date Jun. 7, 1991 PCT Filed Oct. 4, 1989.This invention relates to analogs of thrombolytic agents having a modified kringle domain. More specifically, this invention is directed to TPA type compounds wherein modifications occur in the kringle 1 and kringle 2 domains. This invention is also directed to analogs with one or more changes in the kringle domain of urokinase-type compounds. The compounds of this invention are pharmaceutically useful having particular use in the same manner as TPA and urokinase.
Invention belongs to medicine and medications intended for therapy and hygienic purposes. The composition of the proposed treatment aromatised bath preparation, a sodium chloride, additionally contains an active ingredient, it being a natural essential oil. In order to mark the bath type there is a food dye used. The composition consists of (in grams): sodium chloride - 1,000-1,100; natural essential oil - 0.9-1.2; food dye - 0.9-1.0. As for sodium chloride a table-salt is used. As a treatment essential oils there are used, are the essential oils of lavender, roses, mints, silver fir, sage racemes. Table-salt calibrated crystal, essential oil and food dye saturated, aromatised mineral salt, dissolved in a 36-37 degrees Celsius temperature, produce a therapy and inhalation effect to the human organism at the same time.
After total pancreatectomy patients are treated with exogenous insulin and pancreatic enzyme supplementation in order to treat the endocrine and exocrine insufficiencies inherently occurring postoperatively. In addition to secondary diabetes and insufficient digestive capacity, totally pancreatectomised patients face a high risk of developing non-alcoholic hepatic steatosis. Under normal circumstances non-alcoholic fatty liver disease is regarded as the hepatic manifestation of metabolic syndrome and pathophysiologically related to excess energy intake and insulin resistance resulting in fat accumulation in adipose tissue as well as in the liver. Thus, the high incidence of hepatic steatosis following total pancreatectomy is surprising as patients typically are lean, peripherally insulin sensitive and properly insulinised.Interestingly, the pancreatic hormone glucagon has been implicated in lipid metabolism and recent human data from studies investigating the effect of glucagon receptor antagonism suggest that glucagon signalling may be essential for maintaining a fat-free liver. This makes the investigators speculate that the decreased glucagon levels following pancreatic surgery may play a hitherto unrecognised role in the development of hepatic steatosis after the operation.

The study will include 33 patients scheduled for pancreatectomy (total or pancreaticoduodenectomy). They will be followed for one year. A liver biopsy will be collected during the operation on all patients. After 12 months, participants will undergo magnetic resonance spectroscopy and those who have hepatic lipid content ≥2% will undergo an ultrasound-guided percutaneous liver biopsy. Furthermore, all participants will undergo a metabolic evaulation after one year.
Obesity in the United States has risen to 42 percent of its adult population and is similarly problematic in many other countries. Although the U.S. government has provided education on healthy eating and the need to exercise regularly, behavioral obesity treatments have largely failed to sustain reductions in weight. Self-regulation, and the incorporation of exercise for its psychological impacts on eating, has sometimes been targeted. While there has been sporadic investigation into the carry-over of exercise-related self-regulation to eating-related self-regulation, the present aim is to further inquiry in that area to inform future treatment content for improved effects. Women enrolled in community-based obesity treatments with either a self-regulation (n = 106) or education (n = 54) focus were assessed on changes in exercise- and eating-related self-regulation, negative mood, completed exercise, and weight. Improvements were significantly greater in the self-regulation-focused group. After controlling for initial change in eating-related self-regulation, change in that measure from Month 3 to 6 was significantly predicted by change in exercise-related self-regulation during the initial 3 treatment months. This suggested a carry-over effect. A stronger predictive relationship was associated with the self-regulation-focused treatment. In further analyses, paths from changes in exercise→negative mood→self-regulation of both exercise and eating were significant. Increase in eating-related self-regulation was significantly associated with weight loss over 6, 12, and 24 months. The self-regulation-focused group had stronger relationships, again. Findings suggested utility in targeting exercise-related self-regulation to impact later change in eating-related self-regulation, and the use of exercise-associated mood improvement to bolster participants' self-regulation capabilities.
BACKGROUND: Acute kidney injury (AKI) is a complication often observed in critically ill patients, indicating a worsening prognosis. However, factors predicting AKI in subarachnoid hemorrhage (SAH) patients are unclear. This study aims to elucidate the predictors of AKI occurrence.
METHODS: All patients with SAH admitted to the intensive care unit between 2013 and 2019 were included. Patients with very severe SAH who are unsuitable to receive aggressive treatment, those who previously received a contrast medium at another medical institution within 24 hours before admission, and those on maintenance dialysis were excluded. We retrospectively examined blood tests conducted upon admission, oral medications administered, and the total amount of contrast medium used after initiating treatment to investigate their association with AKI occurrence.
RESULTS: Of the 254 SAH patients treated during the relevant period, 195 (median age 64 years, 72 males) met the inclusion/exclusion criteria, and 32 patients (16.3%) developed AKI. When multivariate analysis was performed using sex, uric acid level, and hemoglobin, which obtained P < 0.01 in the univariate analysis, as variables, only uric acid level was found as an independent predictor of AKI (odds ratio, 1.501; 95% confidence interval, 1.109-2.033, P value of 0.009). There was no difference in the occurrence of AKI between survivors and nonsurvivors (12/163 vs. 2/32, P = 0.824).
CONCLUSIONS: AKI occurred in 16.3% of the patients with SAH. Patients who developed AKI had significantly higher uric acid levels. SAH with high uric acid levels warrants attention for AKI.
The present disclosure provides for base editors which satisfy a need in the art for installation of targeted transversions of guanine (G) to thymine (T), or correspondingly, transversions of adenine (A) to cytosine (C). The domains of the disclosed base editors include a nucleic acid programmable DNA binding protein and a guanine oxidase or a guanine methyltransferase. The base editors may be engineered through the use of continuous or non-continuous evolution systems. In particular, the present disclosure provides for guanine-to-thymine (or cytosine-to-adenine) base editors that can install single-base trans version mutations. In addition, methods for targeted nucleic acid editing are provided. Further provided are pharmaceutical compositions comprising, and vectors and kits useful for the generation of, guanine-to-thymine base editors. Cells containing such vectors and cells containing base editors and guide RNAs are also provided. Further provided are methods of treatment comprising administering the base editors to a subject in need thereof.
Bempedoic acid, a component of NEXLIZET, inhibits renal tubular OAT2 and may increase blood uric acid levels [see Clinical Pharmacology (12.3)]. In the primary hyperlipidemia trials [see Clinical Studies (14.1)], 26% of bempedoic acid-treated patients with normal baseline uric acid values (versus 9.5% placebo) experienced hyperuricemia one or more times, and 3.5% of patients experienced clinically significant hyperuricemia reported as an adverse reaction (versus 1.1% placebo). Increases in uric acid levels usually occurred within the first 4 weeks of treatment initiation, persisted throughout treatment, and returned to baseline following discontinuation of treatment. After 12 weeks of treatment, the mean placebo-adjusted increase in uric acid compared to baseline was 0.8 mg/dL for patients treated with bempedoic acid. In the cardiovascular outcomes trial [see Clinical Studies (14.2)], 16.4% of bempedoic acid-treated patients experienced clinically significant hyperuricemia reported as an adverse reaction (versus 8.2% placebo).

Elevated blood uric acid may lead to the development of gout. In the primary hyperlipidemia trials, gout was reported in 1.5% of patients treated with bempedoic acid versus 0.4% of patients treated with placebo. In the cardiovascular outcomes trial, gout was reported in 3.2% of patients treated with bempedoic acid and 2.2% treated with placebo.

Advise patients to contact their healthcare provider if symptoms of hyperuricemia occur. Assess serum uric acid when clinically indicated. Monitor patients for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
The invention discloses compound oil of zedoary turmeric liquid hard gelatin capsule. It is made up of liquor oil and capsule outer coating. The former is made up of oil of zedoary turmeric, tangerine peel oil, vegetable oil whose proportioning is 9:1:0-40 part by weight. The latter is made up of gelatin or non-gelatin material. Its method of preparation is as follows: extracting oil of zedoary turmeric; extracting tangerine peel oil; adding into vegetable oil; pouring in and sealing. The formed product has the efficiency of conducting qi, removing blood stasis, removing stagnation of qi, and alleviating pain. It can be used in blood stasis due to stagnation of qi, and gastric cavity pain, impaired appetite, epigastric upset overeat caused by food stagnation.
After consuming a meal, 80% of glucose is disposed in skeletal muscle. Our research group has demonstrated that microvascular blood flow in skeletal muscle plays an integral role in this process. Physiological doses of insulin stimulate microvascular blood flow, and that this increase is associated with enhanced glucose uptake by muscle. This microvascular action of insulin is lost during insulin resistance and type 2 diabetes.

The oral glucose tolerance test (GTT) is the gold standard for assessing insulin resistance and pre-diabetes and is used world-wide. However high blood glucose levels following a glucose load may adversely impact on microvascular function. The aim of this project is to determine whether a mixed meal challenge (liquid drink consisting of carbohydrate, fat and protein) is a better test for assessing microvascular-derived insulin resistance.
Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
The invention relates to the technical field of biomedical gene therapy, and discloses a nucleotide sequence for coding human receptor tyrosine kinase Mer and application thereof. The nucleotide sequence of the invention has more than or equal to 95 percent of sameness with the nucleotide sequence shown in SEQ ID NO. 3. The invention proves that the pathological symptoms of retina of a rat with retinitis pigmentosa caused by MERK mutation and the recovery of the function of the retina can be obviously improved by using AAV-MERK drug treatment. AAV-MERK drugs are injected in the vitreous cavity, and the MERK can be efficiently expressed in the retinal pigment epithelium layer and can increase the thickness of the retinal outer nuclear layer. At the same time, the electroretinogram showed that the AAV-MERK drug-treated rats responded strongly to the stimuli compared to the control group. Therefore, the AAV-MERK medicament has the effect of preventing or treating retinitis pigmentosa.
Stenosing tenosynovitis, or more commonly "trigger finger" is a disease that can severely impact a patient's quality of life. Its incidence is said to be 28 persons per 100,000 annually. The disease is manifested in one or more fingers by finger locking in flexion or extension, leading to pain, discomfort and at times, loss of function. Patients frequently report having to snap their fingers back in position to alleviate symptoms. The pathophysiology relates to thickening of the flexor tendon sheath, which can impair tendon gliding within it.

Although multiple treatment strategies are available, it is not entirely clear which treatment offers the best outcome, especially when the finger has not reached end stage locking. In general, corticosteroid injection into the tendon sheath is offered as the first line of treatment. Splinting alone has also been described as a reliable method treatment. However, Patel and Bassini indicated that steroid injection results in fewer recurrences than splinting alone. Surgery is typically reserved for recurrent triggering, cases refractory to injection, or digits locked in flexion. The effects of steroid injection followed by splinting however have not been reported in a comprehensive fashion. It may be that this form of treatment could result in a synergistic effect, which can offer a treatment modality superior to either injection or splinting alone. The purpose of this research study is to determine whether steroid injection followed by splinting is superior to injection alone.
Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each).
The invention provides a product and a product composition for improving sub-health status. The product and the product composition comprise maca and oyster peptides. The composition provided by the invention is unique and reasonable in formula and can be granules, powder, capsules, tablets or the like. The product and the product composition have the functions of adjusting the secretion of hormones, improving the sleeping quality, enhancing the memory ability, reducing blood fat, inhibiting platelet aggregation, improving hyperglycemia symptoms, improving the immunity of human bodies, promoting metabolism and the like, obvious curative effects on climacteric syndrome, puberty essential uterine bleeding, and antenatal or postpartum weakness of women and a very obvious effect on fatigue caused by working pressure and life pressure as well as the physiology regression of middle-aged and aged people. The maca and oyster in the composition are food eaten for thousands of years, and the toxic and side effects of the maca and oyster are not found. The product and the product composition can also contain tartary buckwheat so as to give full play to a relatively good anticancer effect.
Digital CBTi will be offered using the SleepioTM website and supporting Sleepio™ app (Big Health Ltd., London, UK) via 6 sessions training program (spanning 6 to 12 weeks), lasting an average of 20 minutes each, unlocked weekly. The participant will receive the Sleepio intervention as soon as they become assigned.
Hyperkalemia: High dosage of trimethoprim, as used in patients with P. jirovecii pneumonia, induces a progressive but reversible increase of serum potassium concentrations in a substantial number of patients. Even treatment with recommended doses may cause hyperkalemia when trimethoprim is administered to patients with underlying disorders of potassium metabolism, with renal insufficiency, or if drugs known to induce hyperkalemia are given concomitantly. Close monitoring of serum potassium is warranted in these patients. 

Hyponatremia: Severe and symptomatic hyponatremia can occur in patients receiving sulfamethoxazole and trimethoprim, particularly for the treatment of P. jirovecii pneumonia. Evaluation for hyponatremia and appropriate correction is necessary in symptomatic patients to prevent life-threatening complications. 

Crystalluria: During treatment, ensure adequate fluid intake and urinary output to prevent crystalluria. Patients who are “slow acetylators” may be more prone to idiosyncratic reactions to sulfonamides.
Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of TALTZ. Moreover published literature is mixed on potential effects on malignancy risk due to the inhibition of IL-17A activity, the pharmacological action of TALTZ. Some published literature suggests that IL-17A directly promotes cancer cell invasion, suggesting a potential beneficial effect by TALTZ, whereas other reports indicate IL-17A promotes T-cell mediated tumor rejection, suggesting a potential adverse effect by TALTZ. However, neutralization of IL-17A with TALTZ has not been studied in these models. Depletion of IL-17A with a neutralizing antibody inhibited tumor development in mice, suggesting a potential beneficial effect by TALTZ. The relevance of experimental findings in mouse models for malignancy risk in humans is unknown. 

No effects on fertility parameters such as reproductive organs, menstrual cycle length, or sperm analysis were observed in sexually mature cynomolgus monkeys that were administered ixekizumab for 13 weeks at a subcutaneous dose of 50 mg/kg/week (19 times the MRHD on a mg/kg basis). The monkeys were not mated to evaluate fertility.
The LUM Imaging Device will be used to look inside the lumpectomy cavity to see if the dye indicates any areas that may contain residual tumor. If the imaging identifies that there may be cancer cells remaining in the lumpectomy cavity, the surgeon will remove an additional piece of tissue. This process will be continued until a negative reading from the device is obtained or a maximum of 2 shaves of additional tissue has been removed. Patients in this arm will receive the study drug, LUM015.
A skin care composition comprising: (i) a medium having a mixture of two or more immiscible phases; (ii) 0.1 wt. % to 10 wt. % of a terpolymer of vinyl pyrrolidone/acrylic acid/lauryl methacrylate having a relative viscosity of at least 3.3 cps; and (iii) 0.1 wt. % to 20 wt. % of at least one cosmetically/dermatologically acceptable skin care additive; wherein the skin care composition is free from surfactant(s), also discloses skin care composition comprising surfactants. Other embodiments of this application disclose specific sunscreen compositions with/without surfactant systems and methods for providing an enhanced care to skin of humans or animals employing such compositions.
The invention relates to the technical field of traditional Chinese medicines, particularly a traditional Chinese medicine composition for treating chronic enteritis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-15 parts of wrinkled gianthyssop, 10-20 parts of stir-fried Bighead Atractylodes Rhizome, 5-10 parts of Mangnolia officinalis, 5-10 parts of anemone, 6-8 parts of balloonflower, 5-10 parts of cardamon, 5-10 parts of Pinellia tuberifera, 10-20 parts of oriental wormwood, 10-15 parts of licorice root, 20-30 parts of tuckahoe and 4-6 parts of dried ginger. The wrinkled gianthyssop and anemone are used as the monarch drugs; the stir-fried Bighead Atractylodes Rhizome, cardamon and Pinellia tuberifera are used as the ministerial drugs; the Mangnolia officinalis, balloonflower, oriental wormwood and tuckahoe are used as the adjuvant drugs; and the licorice root and dried ginger are used as the guide drugs. The traditional Chinese medicine composition is mainly used for treating the syndrome of interior dampness-heat and the syndrome of damp-heat blocking caused by obstruction of middle jiao. The traditional Chinese medicine composition can be used for treating the following symptoms: gastrointestinal pains, turgor and empty stomach, acid regurgitation, dry and bitter mouthfeel, thirst without desire to drink, yellow urine, constipation, yellowish fur, and rolling and rapid pulse. The traditional Chinese medicine composition is capable of eliminating dampness and heat, regulating the flow of qi and harmonizing the stomach.